regorafenib

Also known as BAY 73-4506

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers.

Research

2,552 papers

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2013
Regorafenib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2018
Regorafenib for the Treatment of Sarcoma.Current treatment options in oncology · 2022
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet (London, England) · 2017
Regorafenib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2014

via PubMed

Wikidata facts

Mass: 482.076881

Show 4 more facts

chemical formula: C₂₁H₁₅ClF₄N₄O₃
canonical SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
World Health Organisation international non-proprietary name: regorafenib
Commons category: Regorafenib

Sources (5)

via Wikidata · CC0

~6 min read